Tag: Hypertension

Clinical Features and Etiology of Recurrent Hypertension after Adrenalectomy

Announcing a new article publication for Cardiovascular Innovations and Applications journal.

Patients who undergo adrenalectomy for unilateral primary aldosteronism (PA) may still develop post-surgery hypertension; however, the clinical characteristics and etiology of patients developing recurrent hypertension after adrenalectomy are unclear. We analyzed the records of 43 patients with recurrent elevated blood pressure after adrenalectomy, who were treated at our center. Standard routine clinical screening workup was used to identify the cause of recurrent hypertension. Causes of recurrent hypertension after adrenalectomy included essential hypertension, primary aldosteronism, obstructive sleep apnea, renal artery stenosis, and Takayasu arteritis. Before adrenalectomy, 39.5% of patients were diagnosed with confirmed or suspected PA, primarily through CT imaging.

Adrenal venous sampling (AVS) tests were not conducted on any patients, and 72.1% patients underwent partial adrenalectomy. Among all patients, elevated blood pressure was observed in 44.2% immediately post-operation, 18.6% within 1 month, 16.3% in 1–6 months, and 20.9% >6 months after operation. Most patients had hypertension of grade 2 and above. Standard endocrine functional assessment and AVS tests should be performed before adrenalectomy to ensure more accurate diagnosis and favorable post-operative outcomes. Additionally, individuals often develop essential hypertension regardless of past adrenal disease.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0092

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Xilan Dong, Qianhui Ling and Jin Bian et al. Clinical Features and Etiology of Recurrent Hypertension after Adrenalectomy. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2023.0092

Loading

Relationship between Serum Selenium Levels and Hypertension: Findings from the National Health and Nutrition Examination Survey, 2009–2018

Announcing a new article publication for Cardiovascular Innovations and Applications journal.

This study was aimed at evaluating the association between serum selenium (Se) levels and hypertension in American adults.

Data were extracted from the United States National Health and Nutrition Examination Survey (NHANES, 2009–2018). Multivariate logistic regression and subgroup analysis were conducted to examine associations between Se and hypertension.

Patients with hypertension had higher serum Se levels than healthy participants (P = 0.01017). After adjustment for demographic and health behaviors, serum Se levels were significantly associated with systolic blood pressure in women (OR = 0.014; 95% CI: 0.001–0.027; P = 0.04174). Serum Se levels were significantly associated with diastolic blood pressure (DBP) in both women and men. In subgroup analysis, serum Se levels were significantly associated with higher diastolic blood pressure (P for trend <0.001).

In summary, this analysis supports a nonlinear association between serum Se levels and the prevalence of hypertension, and higher serum Se levels were associated with higher DBP.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0096

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Wang Lili and Guo Liwei. Relationship between Serum Selenium Levels and Hypertension: Findings from the National Health and Nutrition Examination Survey, 2009–2018. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2023.0096

Loading

Top Ten Breakthroughs in Clinical Hypertension Research in 2022

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Hypertension is a major global public health concern whose disease burden affects an estimated 1.4 billion people worldwide and is associated with 10.8 million deaths annually. Despite substantial advances in medical care, the prevalence of hypertension has markedly increased, owing to population aging; poor treatment adherence; and increases in risk factors, such as excessive salt intake, and overweight and obesity. Consequently, the disability-adjusted life years have increased by 40%, primarily because of elevated risk of stroke, coronary atherosclerosis, heart failure, and kidney failure. Major outstanding problems associated with the treatment and management of hypertension include determining optimal blood pressure targets, developing innovative antihypertensive medications and devices, and implementing effective and feasible hypertension management strategies. To address these challenges, numerous clinical trials are currently underway.

This article highlights the most influential ten clinical studies on hypertension in 2022. The rational use of antihypertensive medications is concluded to be important for effective hypertension management. Important considerations include medication types and dosing times; optimal blood pressure targets; the development of new drugs and therapeutic devices; specific community characteristics, such as village doctor-led care; and healthful diets.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0054

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Qiaoxi Yang and Jun Cai. Top Ten Breakthroughs in Clinical Hypertension Research in 2022. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0054

Loading

Changes in Autonomic Nervous System Function in Patients greater than 60 Years of Age with Coronary Heart Disease, and Normotension or Hypertension: An Observational Study

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  The aim of this observational study was to perform in-depth analysis of autonomic nervous system function in patients older than 60 years of age with coronary artery disease, and normotension or hypertension.

A total of 104 patients older than 60 years with coronary heart disease (CHD) were divided into a normotension group and hypertension (HT) group, and 24-hour Holter monitoring was performed to assess autonomic function.

Among the 104 patients with CHD analyzed, 52 had normotension, and 52 had hypertension. The 24-hour Holter results based on time-domain methods indicated that the values of the time-domain parameters of heart rate variability were significantly lower in the CHD+HT group than the CHD group. Furthermore, during both the daytime and nighttime, the time-domain parameters were significantly lower in the CHD+HT group than the CHD group. No difference was observed in autonomic function during the daytime and nighttime in each group. Values of frequency-domain parameters of heart rate variability were also significantly lower in the CHD+HT group than the CHD group. More patients in the CHD+HT group than the CHD group received percutaneous coronary intervention (57.69% vs. 50% χ2=0.619, P=0.55). In 12 months of follow-up, we found no significant differences in rehospitalization for unstable angina and target lesion revascularization between patients with CHD with normotension versus hypertension.

The heart autonomic nervous system dysfunction in patients older than 60 years with CHD with hypertension was more severe than that in patients with CHD with normotension, and therefore, should receive greater clinical attention.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0038

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Jing-Xiu Li, Jing Wang and Bei-Bei Ding et al. Changes in Autonomic Nervous System Function in Patients >60 Years of Age with Coronary Heart Disease, and Normotension or Hypertension: An Observational Study. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0038

Loading

Advances in Renal Denervation in the Treatment of Hypertension

Hypertension significantly increases the risk of cardiovascular events and it is associated with high rates of disability and mortality. Hypertension is a common cause of cardiovascular and cerebrovascular accidents, which severely affect patients’ quality of life and lifespan. Current treatment strategies for hypertension are based primarily on medication and lifestyle interventions. The renal sympathetic nervous system plays an important role in the pathogenesis of hypertension, and catheter-based renal denervation (RDN) has provided a new concept for the treatment of hypertension. In recent years, studies on RDN have been performed worldwide. This article reviews the latest preclinical research and clinical evidence for RDN.

Announcing a new article publication for Cardiovascular Innovations and Applications journal.   

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0014

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Bin Xiong, Shaojie Chen and Weijie Chen et al. Advances in Renal Denervation in the Treatment of Hypertension. CVIA. 2023. Vol. 7(1). DOI: 10.15212/CVIA.2023.0014

Loading

Optimal Blood Pressure Control Target for Older Patients with Hypertension: A Systematic Review and Meta-Analysis

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study evaluated the optimal systolic blood pressure (SBP) target for older patients with hypertension.

A Bayesian network meta-analysis was conducted. The risk of bias of the included studies was assessed by using a modified version of the Cochrane risk of bias. The trial outcomes comprised the following clinical events: major adverse cardiovascular events (MACE), cardiovascular mortality, all-cause mortality, myocardial infarction, heart failure and stroke.

A total of six trials were included. All treatment therapies were reclassified into three conditions according to the final achieved SBP after intervention (<130 mmHg, 130–139 mmHg and ≥140 mmHg). The results demonstrated that anti-hypertensive treatment with an SBP target <130 mmHg, compared with treatment with an SBP target ≥140 mmHg, significantly decreased the incidence of MACE (OR 0.43, 95%CI 0.19–0.76), but no statistical difference was found in other comparisons. Although the results showed a trend toward more intensive anti-hypertension therapy having better effects on preventing cardiovascular mortality, all-cause mortality, myocardial infarction, heart failure, and stroke, no significant differences were found among groups.

The meta-analysis suggested that SBP <130 mmHg might be the optimal BP control target for patients ≥60 years of age; however, further evidence is required to support these findings.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0008

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Article reference: Yuling Yan, Yue Han and Bin Liu et al. Optimal Blood Pressure Control Target for Older Patients with Hypertension: A Systematic Review and Meta-Analysis. CVIA. 2023. Vol. 7(1). DOI: 10.15212/CVIA.2023.0008

Loading

KSCMS @ GW-ICC Joint Forum – Great Wall International Congress of Cardiology (GW-ICC) 2017 – Practical management of Hypertension in Korean after SPRINT trial

It has become a tradition for world renowned cardiology associations to send delegations to GW-ICC congresses. Cooperation with these international societies is not limited to their attendance at GW-ICC; GW-ICC also holds reciprocal academic sessions at the annual meetings of these eminent societies to introduce important Chinese academic research.

At the 28th GW-ICC in 2017, the Korean Society of Cardio metabolic Syndrome (KSCMS) held a Joint Forum. A video of one of these 2017 sessions is now available to view on the GW-ICC YouTube channel:

Practical management of Hypertension in Korean after SPRINT trial

Presenter: Sang-Hyun Ihm, MD, PhD, Department of Internal Medicine, Catholic University of Korea, Seoul, South Korea.

Dr Sang-Hyun Ihm discusses:

  • Target BP of recent guidelines.
  • Observational studies – lower is better.
  • Updated systemic review and meta analysis.
  • Systolic blood pressure intervention trial (SPRINT).
  • Several issues of SPRINT.

Concluding that:

  • Since AOBP is not generally available in clinical practice, the definition of hypertension should remain BPs >140/90mm Hg.
  • AOBP will be the preferred method of performing in-office BP measurement
  • The target BP should remain to lower BP in most hypertensive patients to <140/90 mmHG.
  • The higher cardiovascular risk: SPRINT eligible patients
    • Target SBP should be <120mmHG using AOBP
  • Others including DM, CKD with overt proteinuria
    • Target BPs should not be changed
  • The balance between benefits and risks should be taken into account for the practice of personalized medicine.
    • If tolerated well, one could attempt to go lower incrementally with careful monitoring.

Further information on the 29th GW-ICC, to be held October 11th -14th, 2018, in Beijing, China, is available on the congress website:

http://www.gw-icc2017.org/en/1/index.jsp

Cardiovascular Innovations and Applications (CVIA) is the official journal of the Great Wall International Cardiology Conference (GW-ICC). CVIA supports GW-ICC in its aims of leading the development of cardiovascular medicine in China, by introducing and promoting new concepts and technologies and strengthening and promoting cooperation amongst Chinese and international cardiology experts. CVIA is available on the IngentaConnect platform http://www.ingentaconnect.com/content/cscript/cvia and at https://dhn.zgc.mybluehostin.me/cvia/. Submissions may be made using Scholar One manuscripts at https:/mc04.manuscriptcentral.com/cvia-journal. There are no author submission or article processing fees.

Twitter: @CVIA_Journal

Facebook: https://www.facebook.com/cvia.journal/

Conference website: http://www.gw-icc2017.org/en/1/index.jsp

Loading